Grifols vs Vertex Pharmaceuticals
GRFS and VRTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GRFS and VRTX compare
Vertex Pharmaceuticals grew revenue faster over the last twelve months (10.2% versus 4.3% for Grifols).
Vertex Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 35.0% compared with 5.3% at Grifols.
Vertex Pharmaceuticals scores higher on the StockData Score (15 against 9 for Grifols), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GRFS | VRTX |
|---|---|---|
| Size and price | ||
| Market cap | – | $142B |
| Share price | $8.10 | $558.88 |
| Change, 1 year | −13.7% | 34.0% |
| Change, 5 years | −33.7% | 190% |
| Beta (5Y) | 0.91 | 0.54 |
| Employees | 1,613 | 600K |
| StockData Score | ||
| Total score | 9 | 15 (better) |
| Valuation score | 0 | 0 |
| Growth score | 2 | 3 (better) |
| Performance score | 4 | 6 (better) |
| Health score | 3 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 32.5× |
| P/S | – | 11.3× |
| P/B | – | 7.0× |
| EV/EBITDA | – | 26.8× |
| P/FCF | – | 37.3× |
| PEG | – | 5.32 |
| FCF yield | – | 2.7% |
| Fair value | – | $407.96 |
| Margin of safety | – | −37.0% |
| Growth | ||
| Revenue growth (TTM) | 4.3% | 10.2% (better) |
| Revenue growth, 5Y average | 7.1% | 14.1% (better) |
| Net income growth (TTM) | 156% (better) | 21.1% |
| EPS growth (TTM) | 157% (better) | 22.4% |
| EPS growth, 5Y average | −8.1% | 8.3% (better) |
| Profitability | ||
| Gross margin | 38.0% | 86.0% (better) |
| Operating margin | 16.5% | 38.0% (better) |
| Net margin | 5.3% | 35.0% (better) |
| FCF margin | 10.4% | 30.2% (better) |
| Return on equity | 7.2% | 23.5% (better) |
| Return on invested capital | 14.6% | 34.4% (better) |
| Financial health | ||
| Debt / equity | 0.41 (better) | 0.00 |
| Net debt / EBITDA | 0.79 | – |
| Interest coverage | 2.0× | – |
| Current ratio | 2.51 | 3.19 (better) |
| Altman Z-score | – | 14.06 |
| Piotroski F-score | 5 | 7 (better) |
| Dividends and buybacks | ||
| Payout ratio | 31.8% | – |
| Buyback yield | – | 1.4% |
| Shareholder yield | – | 1.4% |
| Ownership | ||
| Held by institutions | 20.8% | 95.6% |
| Held by insiders | 0.00% | 0.23% |
| Insider net buying, 12 months | – | −$158M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | – | 1.8% |
Go deeper
- GRFS stock overview
- GRFS income statement
- GRFS valuation and score
- VRTX stock overview
- VRTX income statement
- VRTX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.